Given the rapid clinical progression of prion disease following symptom onset and ASO treatment data in mice suggesting an outsize benefit to early treatment [5], it has been proposed that PrP-lowering agents could be tested clinically in presymptomatic individuals at known risk for genetic prion disease, with a goal of delaying or preventing onset [12]. This evidence concerns the gene PRNP and prion disease.